{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:03:43Z","timestamp":1792839823252,"version":"4.5.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chronic HBV infection can hardly be cured due to the persistence of an intrahepatic pool of viral covalently closed circular DNA (cccDNA) transcription template, which is refractory to current antivirals. The direct analyses of cccDNA quantity and transcriptional activity require an invasive biopsy. Recently, circulating HBV RNA has been identified as a promising noninvasive surrogate marker of cccDNA and can be used for monitoring disease progression and predicting prognosis of patients with chronic HBV infection. To better understand this surrogate biomarker of cccDNA, we reviewed the current knowledge about the molecular characteristics and potential clinical applications of circulating HBV RNA. Specifically, we summarized the reported species and existing forms of circulating HBV RNA and discussed their biogenesis and the capacity of\n                    <jats:italic toggle=\"yes\">de novo<\/jats:italic>\n                    infection by RNA virions. Moreover, we described the potential applications of circulating HBV RNA in different clinical scenarios, such as classifying the phases of chronic HBV infection, analyzing sustained on\u2010treatment and off\u2010treatment outcomes of treated patients, as well as predicting HCC development. Perspectives on future research of circulating HBV RNA were also proposed in this review.\n                  <\/jats:p>","DOI":"10.1002\/hep.32479","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T04:16:04Z","timestamp":1648440964000},"page":"1520-1530","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":58,"title":["Circulating HBV RNA: From biology to clinical applications"],"prefix":"10.1097","volume":"76","author":[{"given":"Rui","family":"Deng","sequence":"first","affiliation":[{"name":"State Key Laboratory of Organ Failure Research,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Organ Failure Research,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Organ Failure Research,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou,China"},{"name":"Cancer Virology Program, UPMC Hillman Cancer Center, Department of Microbiology and Molecular Genetics,University of Pittsburgh,Pittsburgh,Pennsylvania,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-916X","authenticated-orcid":false,"given":"Haitao","family":"Guo","sequence":"additional","affiliation":[{"name":"Cancer Virology Program, UPMC Hillman Cancer Center, Department of Microbiology and Molecular Genetics,University of Pittsburgh,Pittsburgh,Pennsylvania,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5320-227X","authenticated-orcid":false,"given":"Jian","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Organ Failure Research,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"hep32479-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep32479-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2015.08.005","article-title":"Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA\u2010targeting antiviral therapeutics","volume":"122","year":"2015","journal-title":"Antiviral Res"},{"key":"hep32479-bib-0004-20241017","article-title":"Hepatitis B virus cccDNA: formation, regulation and therapeutic potential","volume":"180","year":"2020","journal-title":"Antiviral Res"},{"key":"hep32479-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014report from the 2019 EASL\u2010AASLD HBV Treatment Endpoints Conference","volume":"72","year":"2020","journal-title":"J Hepatol"},{"key":"hep32479-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4254\/wjh.v10.i9.603","article-title":"Progression and status of antiviral monitoring in patients with chronic hepatitis B: from HBsAg to HBV RNA","volume":"10","year":"2018","journal-title":"World J Hepatol"},{"key":"hep32479-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic therapy against chronic hepatitis B","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep32479-bib-0008-20241017","article-title":"New insights on molecular mechanism of hepatitis B virus covalently closed circular DNA formation","volume":"9","year":"2020","journal-title":"Cells"},{"key":"hep32479-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cld.2007.08.002","article-title":"Molecular virology of hepatitis B virus for clinicians","volume":"11","year":"2007","journal-title":"Clin Liver Dis"},{"key":"hep32479-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.antiviral.2018.08.014","article-title":"Host functions used by hepatitis B virus to complete its life cycle: implications for developing host\u2010targeting agents to treat chronic hepatitis B","volume":"158","year":"2018","journal-title":"Antiviral Res"},{"key":"hep32479-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2020.01.028","article-title":"Full\u2010length 5'RACE identifies all major HBV transcripts in HBV\u2010infected hepatocytes and patient serum","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32479-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep32479-bib-0013-20241017","article-title":"Biogenesis and molecular characteristics of serum hepatitis B virus RNA","volume":"16","year":"2020","journal-title":"PLoS Pathog"},{"key":"hep32479-bib-0014-20241017","article-title":"Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid\u2010antibody complexes in addition to virions in chronic hepatitis B patients","volume":"92","year":"2018","journal-title":"J Virol"},{"key":"hep32479-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hep.30844","article-title":"Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination","volume":"71","year":"2020","journal-title":"Hepatology"},{"key":"hep32479-bib-0016-20241017","article-title":"Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"hep32479-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/cid\/ciaa1015","article-title":"Circulating pregenomic HBV RNA is primarily full\u2010length in chronic hepatitis B patients undergoing nucleos(t)ide analogue therapy","volume":"72","year":"2021","journal-title":"Clin Infect Dis"},{"key":"hep32479-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00535-006-1856-4","article-title":"Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy","volume":"41","year":"2006","journal-title":"J Gastroenterol"},{"key":"hep32479-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon Alfa\u20102a and nucleos(t)ide analogues","volume":"213","year":"2016","journal-title":"J Infect Dis"},{"key":"hep32479-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-7091-5633-9_8","article-title":"Absence of free core antigen in anti\u2010HBc negative viremic hepatitis B carriers","volume":"4","year":"1992","journal-title":"Arch Virol Suppl"},{"key":"hep32479-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature12029","article-title":"A pathogenic picornavirus acquires an envelope by hijacking cellular membranes","volume":"496","year":"2013","journal-title":"Nature"},{"key":"hep32479-bib-0022-20241017","article-title":"Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2\u2010miR122\u2010HSP90","volume":"10","year":"2014","journal-title":"PLoS Pathog"},{"key":"hep32479-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.biochi.2017.05.003","article-title":"Characterization of the lipid envelope of exosome encapsulated HEV particles protected from the immune response","volume":"141","year":"2017","journal-title":"Biochimie"},{"key":"hep32479-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real\u2010time PCR experiments","volume":"55","year":"2009","journal-title":"Clin Chem"},{"key":"hep32479-bib-0025-20241017","article-title":"The dual role of an ESCRT\u20100 component HGS in HBV transcription and naked capsid secretion","volume":"11","year":"2015","journal-title":"PLoS Pathog"},{"key":"hep32479-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1462-5822.2010.01557.x","article-title":"Alix regulates egress of hepatitis B virus naked capsid particles in an ESCRT\u2010independent manner","volume":"13","year":"2011","journal-title":"Cell Microbiol"},{"key":"hep32479-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.10.030","article-title":"HBV RNA virion\u2010like particles produced under nucleos(t)ide analogues treatment are mainly replication\u2010deficient","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep32479-bib-0028-20241017","article-title":"The Smc5\/6 complex restricts HBV when localized to ND10 without inducing an innate immune response and is counteracted by the HBV X protein shortly after infection","volume":"12","year":"2017","journal-title":"PLoS One"},{"key":"hep32479-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","article-title":"Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"hep32479-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep32479-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JCM.00760-17","article-title":"Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment?","volume":"55","year":"2017","journal-title":"J Clin Microbiol"},{"key":"hep32479-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/infdis\/jiy270","article-title":"Serum HBV RNA as a predictor of peginterferon Alfa\u20102a response in patients with HBeAg\u2010positive chronic hepatitis B","volume":"218","year":"2018","journal-title":"J Infect Dis"},{"key":"hep32479-bib-0033-20241017","first-page":"71","article-title":"Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment\u2010naive HBV\u2010infected individuals","volume":"99\u2013100","year":"2018","journal-title":"J Clin Virol"},{"key":"hep32479-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/apt.15890","article-title":"Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg\u2010positive chronic hepatitis B treated with nucleos(t)ide analogues","volume":"52","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"hep32479-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy","volume":"18","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32479-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2147\/IDR.S252994","article-title":"Serum hepatitis B virus RNA levels predict HBeAg seroconversion and virological response in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analog","volume":"13","year":"2020","journal-title":"Infect Drug Resist"},{"key":"hep32479-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","article-title":"Combining HBV RNA and hepatitis B core\u2010related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg\u2010positive chronic hepatitis B patients","volume":"222","year":"2020","journal-title":"J Infect Dis"},{"key":"hep32479-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.16538","article-title":"Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment","volume":"54","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"hep32479-bib-0039-20241017","article-title":"Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy","volume":"21","year":"2021","journal-title":"J Infect Dis"},{"key":"hep32479-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/jvh.12908","article-title":"Natural history of serum HBV\u2010RNA in chronic HBV infection","volume":"25","year":"2018","journal-title":"J Viral Hepat"},{"key":"hep32479-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jhep.2017.08.021","article-title":"Relationship between serum HBV\u2010RNA levels and intrahepatic viral as well as histologic activity markers in entecavir\u2010treated patients","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep32479-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3851\/IMP2777","article-title":"On\u2010treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy","volume":"20","year":"2015","journal-title":"Antivir Ther"},{"key":"hep32479-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00535-021-01780-5","article-title":"Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy","volume":"56","year":"2021","journal-title":"J Gastroenterol"},{"key":"hep32479-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jvh.13061","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"26","year":"2019","journal-title":"J Viral Hepat"},{"key":"hep32479-bib-0045-20241017","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.30082","article-title":"Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog\u2010treated or untreated patients during chronic and acute infection","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep32479-bib-0046-20241017","article-title":"Performance of a novel automated assay for the detection and quantification of HBV pregenomica RNA\/circulating RNAs in chronic HBV patients, Poster Abstracts","volume":"74","year":"2021","journal-title":"Hepatology"},{"key":"hep32479-bib-0047-20241017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature\u2010mutation in treated chronic hepatitis B patients","volume":"73","year":"2021","journal-title":"Hepatology"},{"key":"hep32479-bib-0048-20241017","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep32479-bib-0049-20241017","article-title":"Comparison of novel biomarkers with conventional HBV markers among untreated adults with chronic hepatitis B in North America","year":"2021","journal-title":"Hepatology"},{"key":"hep32479-bib-0050-20241017","article-title":"Methodology\u2010dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients","volume":"189","year":"2021","journal-title":"Antiviral Res"},{"key":"hep32479-bib-0051-20241017","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","year":"2014","journal-title":"Science"},{"key":"hep32479-bib-0052-20241017","article-title":"Interferon\u2010inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem\u2010loop structure of viral RNA","volume":"13","year":"2017","journal-title":"PLoS Pathog"},{"key":"hep32479-bib-0053-20241017","article-title":"Comparison of serum hepatitis B virus RNA levels and quasispecies evolution patterns between entecavir and pegylated\u2010interferon mono\u2010treatment in chronic hepatitis B patients","volume":"58","year":"2020","journal-title":"J Clin Microbiol"},{"key":"hep32479-bib-0054-20241017","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12072-020-10015-3","article-title":"Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg\u2010positive patients: a longitudinal cohort study","volume":"14","year":"2020","journal-title":"Hepatol Int"},{"key":"hep32479-bib-0055-20241017","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/apt.16172","article-title":"Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss","volume":"53","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"hep32479-bib-0056-20241017","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciaa013","article-title":"Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg\u2010negative chronic hepatitis B","volume":"72","year":"2021","journal-title":"Clin Infect Dis"},{"key":"hep32479-bib-0057-20241017","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","article-title":"Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo\u2010controlled, phase 1 trial","volume":"6","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep32479-bib-0058-20241017","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ\u201056136379, an HBV capsid assembly modulator, is well\u2010tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","year":"2020","journal-title":"Gastroenterology"},{"key":"hep32479-bib-0059-20241017","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI\u2010H0731, a hepatitis B virus core inhibitor: a randomised, placebo\u2010controlled phase 1 trial","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep32479-bib-0060-20241017","first-page":"1444A","article-title":"First results with RNA interference (RNAi) in chronic hepatitis B (CHB) using ARO\u2010HBV","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep32479-bib-0061-20241017","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep32479-bib-0062-20241017","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep32479-bib-0063-20241017","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","year":"2021","journal-title":"Hepatol Int"},{"key":"hep32479-bib-0064-20241017","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and hepatitis B core\u2010related antigen predict outcomes in hepatitis B e antigen\u2010negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"hep32479-bib-0065-20241017","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg\u2010negative chronic hepatitis B patients","volume":"74","year":"2021","journal-title":"J Hepatol"},{"key":"hep32479-bib-0066-20241017","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/hep.31850","article-title":"HBV\u2010pgRNA increases the stemness and promotes the development of HBV\u2010related HCC through reciprocal regulation with IGF2BP3","volume":"74","year":"2021","journal-title":"Hepatology"},{"key":"hep32479-bib-0067-20241017","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3748\/wjg.v24.i21.2261","article-title":"Hepatitis B virus pathogenesis: fresh insights into hepatitis B virus RNA","volume":"24","year":"2018","journal-title":"World J Gastroenterol"},{"key":"hep32479-bib-0068-20241017","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJM198110293051807","article-title":"Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post\u2010mortem tissue specimens","volume":"305","year":"1981","journal-title":"N Engl J Med"},{"key":"hep32479-bib-0069-20241017","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1073\/pnas.1808319115","article-title":"N6\u2010methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle","volume":"115","year":"2018","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32479","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:55:56Z","timestamp":1729194956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32479","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"assertion":[{"value":"2022-01-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}